Biokine Therapeutics is a private biopharmaceutical company focused on developing novel therapeutics to treat cancer. Biokine’s lead product, motixafortide (BKT140/BL-8040) is a novel selective inhibitor of the CXCR4 chemokine receptor. Motixafortide was licensed to BioLineRx (NASDAQ: BLRX) and successfully completed a Phase 3 study in stem-cell mobilization for autologous bone-marrow transplantation. BioLineRx is preparing the NDA Motixafortide with a planned submission in Q3-2022.

Motixafortide is also being evaluated in a phase 2 clinical studies, in US and China, as treatment for pancreatic cancer in combination with immune therapy and chemotherapy.